

CanREValue

Value-based decisions from Real World Evidence

Newsletter

Issue 5 | Spring 2019

Study Objectives:

Objective 1: (Completed & Ongoing)

- ❖ Develop comprehensive understanding of the current state of RWE nationally & internationally
- ❖ Keep current on emerging/new information related to RWE in Canada and Beyond

Objective 2: (Established & Ongoing)

- ❖ Establish formal national working groups dedicated to policy and methodological application of RWE, and collaboratively & iteratively develop a working framework

Objective 3: (Piloting)

- ❖ Validate the developed framework through the completion of multi-province RWE project


Objective 4: (Ongoing)

- ❖ Employ knowledge translation strategies to establish and integrate the final RWE framework

NEW CanREValue WEBSITE LAUNCHED!

We are excited to report that we have launched an initial version of the CanREValue website, hosted by the Canadian Centre for Applied Research in Cancer Control (ARCC) at <https://cc-arcc.ca/canrevalue/>. It is our vision that this site will be a hub for all CanREValue related information, and provide a landing point not only for our team, but for the wider community interested in cancer control and real world evidence. As we continue to develop these pages, we would value any input or feedback you can provide – you can email us at our new central inbox: CanREValue@cc-arcc.ca or reach out to Rebecca Mercer directly at Rebecca.Mercer@cancercare.on.ca.

This edition of our newsletter will provide an update on our upcoming in-person meeting and the 2019 ARCC conference, as well as give you some more information about our Project Manager Wei. As usual, we will also provide updates about current work. Should you have any questions, comments, or feedback, please let us know by emailing WeiFang.Dai@cancercare.on.ca.



Sample Screen Captures from the CanREValue Website. Left – Main landing page. Right – Sample resource page.

Member Spotlight – Wei Fang Dai, CanREValue Project Manager

We know you are all familiar with Wei who has been taking on overall project management for CanREValue since day 1. In addition, Wei works on a number of other RWE initiatives with ARCC and CCO. We sat down with Wei to learn a bit more about her:



Q: What is your educational background and how did it lead to an interest in RWE?

After completing a HBSc degree at University of Toronto, I went on to pursue my MPH in epidemiology and comparative effectiveness outcomes research at Columbia University. I was especially interested in my courses on health economics, modelling and outcomes research. After graduating, I began working on the CanREValue project and other RWE initiatives with the Pharmacoeconomics Unit at CCO & ARCC, which allowed me to continue learning more about this evolving field.

Q: What aspect of the CanREValue project are you the most excited to work on?

I am very excited about launching objective 3. All of us have dedicated so much hard work to developing the first draft of the framework and it will be really exciting to see it in action!

Q: What are some of your personal hobbies?

Some of my personal hobbies includes listening to podcasts, playing board games, and rock climbing.

Q: How can we reach you?

You can probably find an email from me in your inbox to reply to! But just in case, you can email me anytime at WeiFang.Dai@cancercare.on.ca – I would love to hear from you and look forward to working with you over the next year!

What's Happening?

Working Group	Updates
RWE Planning and Drug Selection	<ul style="list-style-type: none">• Convened for a teleconference in March, 2019• Drafted report on the progress of the working group• Developed survey on the prioritization process
RWE Data	<ul style="list-style-type: none">• Convened for a Teleconference in January, 2019• Assessed the capability of each province to conduct RWE evaluation on three drug candidates with post-meeting materials• Updated the report on data elements based on each provinces' feedback
RWE Method	<ul style="list-style-type: none">• Convened for a teleconference in March, 2019• Drafted outline of report on the methodologies to deal with uncertainties related to survival outcomes
RWE Uptake and Reassessment	<ul style="list-style-type: none">• Convened for a teleconference in February, 2019• Worked on refining a report to be circulated to obtain feedback from stakeholder groups which will be facilitated by the Engagement WG• Developed & circulated survey to working group members about engagement questions for different stakeholders
Stakeholder Engagement	<ul style="list-style-type: none">• Presented at CCSN Webinar• Teleconference scheduled in April

Recent Presentations

- ❖ CCSN Recorded Webinar – March 7, 2019. View Slides by [Clicking Here](#)

CanREValue at #CADTH2019

The qualitative study conducted by Dr. Yvonne Bombard's team will be presented at CADTH Symposium 2019.

CanREValue at #ARCC2019

The 2019 ARCC Conference is happening May 27-28 at the Halifax convention centre, ahead of the in-person CanREValue meetings. ARCC2019 will feature a number of sessions and presentations relevant to CanREValue, including CanREValue specific abstracts. If you will be attending our in-person meetings, we will also cover your attendance at ARCC2019 should you be interested – email Rebecca.Mercer@cancercare.on.ca to receive a registration code if you have not already been sent one.

Plenary Sessions:

- 1. Mammography Screening for Breast Cancer in Canada – Different Views** While not structured as a formal debate, this session will explore some of the controversy surrounding mammography screening in Canada. A discussion on current screening programs and exploration of future directions and opportunities will be included.
- 2. Public Reimbursement of Oncology Drugs – International Perspectives** This session will feature speakers from different jurisdictions (Canada, UK, Poland, Netherlands) who will share experiences and lessons learnt. We are especially proud that CanREValue Methods Working Group member [Dr. Nicholas Latimer](#) will present the UK perspective at this session.

CavREValue Specific Presentations

- A Reassessment Framework Developed by the CanREValue Collaborative.* Oral Presentation by Alex Chambers, Chair, Uptake & Reassessment Working Group & Director – panCanadian Oncology Drug Review.
- Incorporating Real World Evidence Into Cancer Drug Funding Decisions In Canada: A Qualitative Study Of Stakeholders' Perspectives.* Oral Presentation by Marc Clausen, Qualitative Research Manager, St. Michael's Hospital.

Related RWE work

We also want to update you of some presentations on related RWE work we have been working on:

- ISPOR 2019:
 - CATALYST project funded by CIHR
 - Poster on the real-world cost-effectiveness of 2nd line ipilimumab for metastatic melanoma
- CADTH 2019:
 - Multi-provincial (British Columbia, Saskatchewan, and Ontario) project funded by Canadian Partnership Against Cancer
 - Oral presentation on real-world safety of bevacizumab for metastatic colorectal cancer
 - Poster on the real-world effectiveness & cost-effectiveness of bevacizumab for metastatic colorectal cancer
 - CATALYST project funded by CIHR
 - Poster on the real-world effectiveness & safety of 2nd line ipilimumab for metastatic melanoma

Next Steps

- ❖ Launch Objective 3 – testing framework & conducting RWE projects in various provinces
- ❖ In-Person Meeting May 29, 2019

CanREValue

Value-based decisions from Real World Evidence